HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$106.25
−1.57%Price chart
Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15
Key dataSep 15, 2026
Open$107.59
From 52W high−4.07%
Volume1.05M
Market cap$12.06B
P/E (TTM)30.2x
P/S (TTM)7.2x
Div yield—
Key dataSep 15, 2026
Open
$107.59
From 52W high
−4.07%
Volume
1.05M
Market cap
$12.06B
ValuationView details →
P/E (Fwd)
11.1x
EV/EBITDA
19.6x
P/E (TTM)
30.2x
RSI (14)
60.2
MomentumView details →
1D Return
−1.57%
YTD Return
+58.78%
SummaryUpdated Jun 1, 2026
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a San Diego-based biopharma technology platform company founded in 1998 that went public in 2004. The company has evolved from a traditional biotechnology firm into a specialized drug delivery technology platform, leveraging its proprietary ENHANZE technology to enable pharmaceutical companies to convert intravenous biologics into more convenient subcutaneous formulations. Over the past decade, Halozyme has transformed its business model from primarily developing its own drugs to licensing its platform technology to major pharmaceutical partners, creating a highly scalable and profitable royalty-based revenue stream.
Similar companies
Latest newsMore news →
Halozyme Therapeutics reported record second-quarter fiscal 2026 revenue of $481 million, up 48% year over year, with non-GAAP diluted EPS of $1.90, and raised its full-year 2026 guidance.5d agoAllworth Financial LP acquired a new stake in Halozyme Therapeutics, Inc. during the second quarter, buying 37,664 shares valued at approximately $2,948,000.25d agoAmundi acquired additional shares of Halozyme Therapeutics, increasing its stake by 503.5% during the quarter.41d ago